Lung cancer trials in China

In China 1143 Also abroad 2744

1,143 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
A Clinical Study of HS-IT101 Injection in Patients With Advanced Non-Small Cell Lung Cancer(FASTIL-Lung02)
Where
Shanghai
Age
18 years to 75 years
People
24
Run by
Hangzhou Huasai Biomedicine Co., Ltd.
See details and how to joinNCT07830342
No phaseNot yet taking people in China
MRD-Guided Aumolertinib-Based Adjuvant Therapy for Resected EGFR-Mutant NSCLC
Where
Beijing
Age
18 years and over
People
50
Run by
Peking University People's Hospital
See details and how to joinNCT07873086
Phase 2Not yet taking people in China
Prospective Phase II Study of Concurrent Radiotherapy Combined With Full-Course Immunotherapy or Consolidation Immunotherapy for Locally Advanced NSCLC
Where
Guangzhou
Age
18 years to 75 years
People
256
Run by
Sun Yat-sen University
See details and how to joinNCT07874464
Phase 1/2Taking people
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Where
Beijing, Changsha, Chongqing, Guangzhou, Kunming, Shandong
Age
18 years and over
People
460 worldwide
Run by
AstraZeneca
See details and how to joinNCT05123482 · EU 2022-502759-70-01
Phase 1/2Taking people
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Where
Beijing, Jinan, Shanghai, Suzhou
Age
18 years and over
People
554 worldwide
Run by
Institut de Recherches Internationales Servier
See details and how to joinNCT05786924 · EU 2025-523474-16-00
Phase 1Taking people
Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors
Where
Beijing
Age
18 years and over
People
167
Run by
Shandong Boan Biotechnology Co., Ltd
See details and how to joinNCT06596915
Phase 2Taking people
Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer.
Where
Jinan
Age
18 years to 75 years
People
35
Run by
Shandong Cancer Hospital and Institute
See details and how to joinNCT06778382
Phase 2Taking people
Tislelizumab Combined With Anlotinib and Nab-paclitaxel in II-III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study
Where
Jinan
Age
18 years to 75 years
People
34
Run by
Qilu Hospital of Shandong University
See details and how to joinNCT07089199
No phaseTaking people
CAIX-targeted PET/CT in Solid Tumors
Where
Wuhan
Age
18 years and over
People
100
Run by
Zhongnan Hospital
See details and how to joinNCT07833085
Phase 2Not yet taking people in China
A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)
Where
Beijing, Changsha Shi, Chengdu, Shanghai
Age
18 years and over
People
80 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07871214
Phase 1/2Taking people
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Where
Chongqing, Hangzhou, Tianjin, Wuhan
Age
18 years and over
People
1,438 worldwide
Run by
BioNTech SE
See details and how to joinNCT07070232 · EU 2024-517261-16-00
No phaseTaking people
CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC
Where
Chengdu
Age
18 years and over
People
590
Run by
AstraZeneca
See details and how to joinNCT07413757
Phase 2Taking people
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
Where
Beijing, Fuzhou, Hangzhou, Nanchang, Shanghai, Wuhan, Zhengzhou
Age
18 years and over
People
40 worldwide
Run by
Pfizer
See details and how to joinNCT07476287 · EU 2025-524686-24-00
Phase 3Taking people
SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC
Where
Beijing
Age
18 years to 80 years
People
340
Run by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT06457906
Phase 3Taking people
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Where
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Huizhou, Jiangmen, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Wenzhou, Wuhan, Xiangyang, Xinxiang, Yangzhou, Zhengzhou
Age
18 years and over
People
1,410 worldwide
Run by
Pfizer
See details and how to joinNCT07222566 · EU 2025-523461-17-01
Phase 2/3Taking people
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
Where
Guangzhou, Shanghai
Age
18 years and over
People
550 worldwide
Run by
Pfizer
See details and how to joinNCT07226999 · EU 2025-523522-41-00
Phase 1/2Taking people
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Where
Beijing, Fuzhou, Nanjing, Shanghai, Taizhou, Wuhan
Age
18 years and over
People
162 worldwide
Run by
Pfizer
See details and how to joinNCT07227298 · EU 2025-523526-40-00
Phase 2Taking people
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
Where
Beijing, Guangzhou, Jinan, Shanghai
Age
18 years and over
People
120 worldwide
Run by
Pfizer
See details and how to joinNCT07489066 · EU 2025-524825-42-00
Phase 2/3Not yet taking people in China
A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Where
Anyang, Beijing, Chongqing, Dalian, Guangzhou, Harbin, Hefei, Jinan, Nanning, Qingdao, Shijiazhuang, Wuha, Xuzhou, Zhenzhou, Zunyi
Age
18 days to 75 days
People
1,438
Run by
Shanghai Henlius Biotech
See details and how to joinNCT07865910
Phase 2Taking people
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
Where
Beijing, Chongqing, Fuzhou, Nanjing, Nanning, Shanghai, Zhengzhou
Age
18 years and over
People
144 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06780098 · EU 2024-518839-11-00
Phase 3Taking people
Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Combined With Monoclonal Antibody in Locally Advanced NSCLC
Where
Shanghai
Age
18 years and over
People
290
Run by
Shanghai Pulmonary Hospital, Shanghai, China
See details and how to joinNCT07863999
Phase 1/2Taking people
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
Where
Beijing, Chengdu, Fuzhou, Hangzhou, Nanjing, Shanghai
Age
18 years and over
People
327 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06780137 · EU 2024-517926-25-00
Phase 1/2Taking people
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Where
Chengdu, Chongqing, Guangzhou, Jinan, Xi'an, Zhengzhou
Age
18 years to 130 years
People
622 worldwide
Run by
AstraZeneca
See details and how to joinNCT05797168 · EU 2022-502576-23-00
Phase 2/3Taking people
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Where
Beijing, Chengdu, Fuzhou, Guangzhou, Nanchang, Shanghai, Wuhan
Age
18 years and over
People
854 worldwide
Run by
AbbVie
See details and how to joinNCT07005102
Phase 2/3Taking people
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Where
Guangzhou, Nanchang, Shanghai, Ürümqi
Age
18 years and over
People
490 worldwide
Run by
AbbVie
See details and how to joinNCT07155187 · EU 2025-521124-29-00